SCHEMBL23200086

SCHEMBL23200086

COc1ccc(NC(=O)N(Cc2cccs2)C2CCCC2)cc1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.76
LMNA P02545 1/20 0.59
TSHR P16473 1/20 0.56
HTT P42858 1/20 0.56
ATM Q13315 1/20 0.56
TRPM8 Q7Z2W7 2/20 0.56
MAPT P10636 2/20 0.55
POLB P06746 1/20 0.51
USP2 O75604 1/20 0.51
RECQL P46063 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
YAP1 P46937 1/20 0.49
TEAD4 Q15561 1/20 0.49
UBE2M P61081 1/20 0.49
DCUN1D1 Q96GG9 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23200239 0.86 ALDH1A1 (1.00) ALDH1A1LMNATSHRHTTATM
SCHEMBL23200234 0.86 ALDH1A1 (0.77) ALDH1A1LMNATSHRHTTTRPM8
SCHEMBL23200158 0.86 ALDH1A1 (0.77) ALDH1A1LMNATSHRHTTTRPM8
SCHEMBL23199953 0.85 MAPT (0.62) ALDH1A1LMNATSHRHTTATM
SCHEMBL23200122 0.85 ALDH1A1 (0.80) ALDH1A1LMNATSHRHTTTRPM8
SCHEMBL23199939 0.85 ALDH1A1 (0.80) ALDH1A1LMNATSHRHTTTRPM8
SCHEMBL23199988 0.84 ALDH1A1 (0.79) ALDH1A1LMNATSHRHTTTRPM8
SCHEMBL23200149 0.84 ALDH1A1 (0.82) ALDH1A1LMNATSHRHTTTRPM8
SCHEMBL9264006 0.82 ROCK2 (0.61) ALDH1A1MAPTPOLBUSP2UBE2M
SCHEMBL23200146 0.81 ALDH1A1 (0.72) ALDH1A1LMNATSHRHTTTRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 US claimed
EP-3802503-A1 UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM E-Therapeutics plc (GB) 2021-04-14 EP claimed
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 US disclosed
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM E-THERAPEUTICS PLC (GB) 2021-08-05 US disclosed
EP-3802503-A1 UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM E-Therapeutics plc (GB) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238139-A1 MODULATORS OF TRYPTOPHAN CATABOLISM TPH1, KYNU, TPH2 ALDH1A1 606/4885LMNA 4541/4885TSHR 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.